BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dorothée G, Vergnon I, Menez J, Echchakir H, Grunenwald D, Kubin M, Chouaib S, Mami-Chouaib F. Tumor-infiltrating CD4+ T lymphocytes express APO2 ligand (APO2L)/TRAIL upon specific stimulation with autologous lung carcinoma cells: role of IFN-alpha on APO2L/TRAIL expression and -mediated cytotoxicity. J Immunol. 2002;169:809-817. [PMID: 12097384 DOI: 10.4049/jimmunol.169.2.809] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 2.6] [Reference Citation Analysis]
Number Citing Articles
1 Dorothée G, Vergnon I, El Hage F, Chansac BLM, Ferrand V, Lécluse Y, Opolon P, Chouaib S, Bismuth G, Mami-chouaib F. In Situ Sensory Adaptation of Tumor-Infiltrating T Lymphocytes to Peptide-MHC Levels Elicits Strong Antitumor Reactivity. J Immunol 2005;174:6888-97. [DOI: 10.4049/jimmunol.174.11.6888] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
2 Le Floc'h A, Jalil A, Vergnon I, Le Maux Chansac B, Lazar V, Bismuth G, Chouaib S, Mami-Chouaib F. Alpha E beta 7 integrin interaction with E-cadherin promotes antitumor CTL activity by triggering lytic granule polarization and exocytosis. J Exp Med 2007;204:559-70. [PMID: 17325197 DOI: 10.1084/jem.20061524] [Cited by in Crossref: 167] [Cited by in F6Publishing: 150] [Article Influence: 11.1] [Reference Citation Analysis]
3 Umeshappa CS, Huang H, Xie Y, Wei Y, Mulligan SJ, Deng Y, Xiang J. CD4+ Th-APC with acquired peptide/MHC class I and II complexes stimulate type 1 helper CD4+ and central memory CD8+ T cell responses. J Immunol 2009;182:193-206. [PMID: 19109150 DOI: 10.4049/jimmunol.182.1.193] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 3.4] [Reference Citation Analysis]
4 Schultz ES, Schuler-thurner B, Stroobant V, Jenne L, Berger TG, Thielemanns K, van der Bruggen P, Schuler G. Functional Analysis of Tumor-Specific Th Cell Responses Detected in Melanoma Patients after Dendritic Cell-Based Immunotherapy. J Immunol 2004;172:1304-10. [DOI: 10.4049/jimmunol.172.2.1304] [Cited by in Crossref: 56] [Cited by in F6Publishing: 46] [Article Influence: 3.1] [Reference Citation Analysis]
5 Chen L, Qiu Y, Hao Z, Cai J, Zhang S, Liu Y, Zheng D. A novel humanized anti-tumor necrosis factor-related apoptosis-inducing ligand-R2 monoclonal antibody induces apoptotic and autophagic cell death. IUBMB Life 2017;69:735-44. [PMID: 28748573 DOI: 10.1002/iub.1659] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
6 Le Maux Chansac B, Moretta A, Vergnon I, Opolon P, Lécluse Y, Grunenwald D, Kubin M, Soria JC, Chouaib S, Mami-Chouaib F. NK cells infiltrating a MHC class I-deficient lung adenocarcinoma display impaired cytotoxic activity toward autologous tumor cells associated with altered NK cell-triggering receptors. J Immunol 2005;175:5790-8. [PMID: 16237071 DOI: 10.4049/jimmunol.175.9.5790] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 3.5] [Reference Citation Analysis]
7 Coler RN, Hudson T, Hughes S, Huang PW, Beebe EA, Orr MT. Vaccination Produces CD4 T Cells with a Novel CD154-CD40-Dependent Cytolytic Mechanism. J Immunol 2015;195:3190-7. [PMID: 26297758 DOI: 10.4049/jimmunol.1501118] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
8 Cartland SP, Erlich JH, Kavurma MM. TRAIL deficiency contributes to diabetic nephropathy in fat-fed ApoE-/- mice. PLoS One. 2014;9:e92952. [PMID: 24667560 DOI: 10.1371/journal.pone.0092952] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
9 Tong L, Schuhmacher C, Assenmacher M, Zänker K, Jähn P. Multiplex and functional detection of antigen-specific human T cells by ITRA—Indirect T cell recognition assay. Journal of Immunological Methods 2014;404:13-23. [DOI: 10.1016/j.jim.2013.11.027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
10 Spierings DC, de Vries EG, Vellenga E, van den Heuvel FA, Koornstra JJ, Wesseling J, Hollema H, de Jong S. Tissue distribution of the death ligand TRAIL and its receptors. J Histochem Cytochem 2004;52:821-31. [PMID: 15150291 DOI: 10.1369/jhc.3A6112.2004] [Cited by in Crossref: 119] [Cited by in F6Publishing: 46] [Article Influence: 6.6] [Reference Citation Analysis]
11 Liu Y, Zhang T, Zhang L, Zhao C, Zhang Z, Wang Z, Gu M, Li W, Li B. Combined application of bevacizumab and PD-1 blockade displays durable treatment effects by increasing the infiltration and cytotoxic function of CD8+ T cells in lung cancer. Immunotherapy 2022. [PMID: 35574588 DOI: 10.2217/imt-2021-0196] [Reference Citation Analysis]
12 Rossin A, Miloro G, Hueber AO. TRAIL and FasL Functions in Cancer and Autoimmune Diseases: Towards an Increasing Complexity. Cancers (Basel) 2019;11:E639. [PMID: 31072029 DOI: 10.3390/cancers11050639] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
13 Moloney FJ, Halliday GM. Nonmelanoma Skin Cancer. In: Gaspari AA, Tyring SK, editors. Clinical and Basic Immunodermatology. London: Springer; 2008. pp. 223-43. [DOI: 10.1007/978-1-84800-165-7_16] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 de Looff M, de Jong S, Kruyt FAE. Multiple Interactions Between Cancer Cells and the Tumor Microenvironment Modulate TRAIL Signaling: Implications for TRAIL Receptor Targeted Therapy. Front Immunol 2019;10:1530. [PMID: 31333662 DOI: 10.3389/fimmu.2019.01530] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
15 Cassatella MA, Huber V, Calzetti F, Margotto D, Tamassia N, Peri G, Mantovani A, Rivoltini L, Tecchio C. Interferon-activated neutrophils store a TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) intracellular pool that is readily mobilizable following exposure to proinflammatory mediators. Journal of Leukocyte Biology 2006;79:123-32. [DOI: 10.1189/jlb.0805431] [Cited by in Crossref: 58] [Cited by in F6Publishing: 59] [Article Influence: 3.4] [Reference Citation Analysis]
16 Veith I, Mencattini A, Picant V, Serra M, Leclerc M, Comes MC, Mami-Chouaib F, Camonis J, Descroix S, Shirvani H, Mechta-Grigoriou F, Zalcman G, Parrini MC, Martinelli E. Apoptosis mapping in space and time of 3D tumor ecosystems reveals transmissibility of cytotoxic cancer death. PLoS Comput Biol 2021;17:e1008870. [PMID: 33784299 DOI: 10.1371/journal.pcbi.1008870] [Reference Citation Analysis]
17 Franco-Molina MA, Mendoza-Gamboa E, Zapata-Benavides P, Vera-García ME, Castillo-Tello P, García de la Fuente A, Mendoza RD, Garza RG, Támez-Guerra RS, Rodríguez-Padilla C. IMMUNEPOTENT CRP (bovine dialyzable leukocyte extract) adjuvant immunotherapy: a phase I study in non-small cell lung cancer patients. Cytotherapy 2008;10:490-6. [PMID: 18821359 DOI: 10.1080/14653240802165681] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
18 Cardoso Alves L, Corazza N, Micheau O, Krebs P. The multifaceted role of TRAIL signaling in cancer and immunity. FEBS J 2020. [PMID: 33215853 DOI: 10.1111/febs.15637] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
19 Sag D, Ayyildiz ZO, Gunalp S, Wingender G. The Role of TRAIL/DRs in the Modulation of Immune Cells and Responses. Cancers (Basel) 2019;11:E1469. [PMID: 31574961 DOI: 10.3390/cancers11101469] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
20 Homma S, Komita H, Sagawa Y, Ohno T, Toda G. Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12. Immunology. 2005;115:451-461. [PMID: 16011514 DOI: 10.1111/j.1365-2567.2005.02179.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 2.0] [Reference Citation Analysis]
21 Kirchner M, Kluck K, Brandt R, Volckmar AL, Penzel R, Kazdal D, Endris V, Neumann O, Seker-Cin H, Goldschmid H, Glade J, Allgäuer M, Kriegsmann M, Winter H, Muley T, Perner S, Frost N, Reck M, Fröhling S, Schirmacher P, Thomas M, Budczies J, Christopoulos P, Stenzinger A. The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma. ESMO Open 2021;6:100253. [PMID: 34487971 DOI: 10.1016/j.esmoop.2021.100253] [Reference Citation Analysis]
22 Dubská L, Andera L, Sheard MA. HER2 signaling downregulation by trastuzumab and suppression of the PI3K/Akt pathway: an unexpected effect on TRAIL-induced apoptosis. FEBS Lett 2005;579:4149-58. [PMID: 16023111 DOI: 10.1016/j.febslet.2005.06.047] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis]
23 Jazirehi AR, Kurdistani SK, Economou JS. Histone deacetylase inhibitor sensitizes apoptosis-resistant melanomas to cytotoxic human T lymphocytes through regulation of TRAIL/DR5 pathway. J Immunol 2014;192:3981-9. [PMID: 24639349 DOI: 10.4049/jimmunol.1302532] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
24 Tabbekh M, Franciszkiewicz K, Haouas H, Lécluse Y, Benihoud K, Raman C, Mami-Chouaib F. Rescue of tumor-infiltrating lymphocytes from activation-induced cell death enhances the antitumor CTL response in CD5-deficient mice. J Immunol 2011;187:102-9. [PMID: 21622855 DOI: 10.4049/jimmunol.1004145] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
25 Hou L, Zhang H, Xu P, Zhang L, Zhang X, Sun Y, Huang X, Wu K. Effect of vitamin E succinate on the expression of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor in gastric cancer cells and CD4(+) T cells. Mol Biosyst 2015;11:3119-28. [PMID: 26378383 DOI: 10.1039/c5mb00350d] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
26 Chen LH, Liu XS, Wang WY, Han WN, Pan BR, Jin BQ. Localization of TRAIL/TRAILR in fetal pancreas. World J Gastroenterol 2003; 9(2): 334-337 [PMID: 12532461 DOI: 10.3748/wjg.v9.i2.334] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
27 Kim HM, Kang JS, Kim JY, Park S, Kim HS, Lee YJ, Yun J, Hong JT, Kim Y, Han S. Evaluation of antidiabetic activity of polysaccharide isolated from Phellinus linteus in non-obese diabetic mouse. International Immunopharmacology 2010;10:72-8. [DOI: 10.1016/j.intimp.2009.09.024] [Cited by in Crossref: 41] [Cited by in F6Publishing: 29] [Article Influence: 3.4] [Reference Citation Analysis]
28 Gómez-Benito M, Balsas P, Bosque A, Anel A, Marzo I, Naval J. Apo2L/TRAIL is an indirect mediator of apoptosis induced by interferon-alpha in human myeloma cells. FEBS Lett 2005;579:6217-22. [PMID: 16246331 DOI: 10.1016/j.febslet.2005.10.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
29 Zerafa N, Westwood JA, Cretney E, Mitchell S, Waring P, Iezzi M, Smyth MJ. Cutting edge: TRAIL deficiency accelerates hematological malignancies. J Immunol 2005;175:5586-90. [PMID: 16237043 DOI: 10.4049/jimmunol.175.9.5586] [Cited by in Crossref: 114] [Cited by in F6Publishing: 105] [Article Influence: 6.7] [Reference Citation Analysis]
30 Diaz Y, Gonzalez A, Lopez A, Perez R, Vazquez AM, Montero E. Anti-ganglioside anti-idiotypic monoclonal antibody-based cancer vaccine induces apoptosis and antiangiogenic effect in a metastatic lung carcinoma. Cancer Immunol Immunother 2009;58:1117-28. [DOI: 10.1007/s00262-008-0634-y] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
31 Durgeau A, Virk Y, Corgnac S, Mami-Chouaib F. Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy. Front Immunol 2018;9:14. [PMID: 29403496 DOI: 10.3389/fimmu.2018.00014] [Cited by in Crossref: 158] [Cited by in F6Publishing: 148] [Article Influence: 39.5] [Reference Citation Analysis]
32 Breckpot K, Dullaers M, Bonehill A, Van Meirvenne S, Heirman C, De Greef C, van der Bruggen P, Thielemans K. Lentivirally transduced dendritic cells as a tool for cancer immunotherapy. J Gene Med 2003;5:654-67. [DOI: 10.1002/jgm.400] [Cited by in Crossref: 133] [Cited by in F6Publishing: 123] [Article Influence: 7.0] [Reference Citation Analysis]
33 Leclerc M, Voilin E, Gros G, Corgnac S, de Montpréville V, Validire P, Bismuth G, Mami-Chouaib F. Regulation of antitumour CD8 T-cell immunity and checkpoint blockade immunotherapy by Neuropilin-1. Nat Commun 2019;10:3345. [PMID: 31350404 DOI: 10.1038/s41467-019-11280-z] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 11.7] [Reference Citation Analysis]
34 Hoek KL, Greer MJ, McClanahan KG, Nazmi A, Piazuelo MB, Singh K, Wilson KT, Olivares-Villagómez D. Granzyme B prevents aberrant IL-17 production and intestinal pathogenicity in CD4+ T cells. Mucosal Immunol 2021;14:1088-99. [PMID: 34183776 DOI: 10.1038/s41385-021-00427-1] [Reference Citation Analysis]
35 Kuwashima N, Nishimura F, Eguchi J, Sato H, Hatano M, Tsugawa T, Sakaida T, Dusak JE, Fellows-Mayle WK, Papworth GD, Watkins SC, Gambotto A, Pollack IF, Storkus WJ, Okada H. Delivery of dendritic cells engineered to secrete IFN-alpha into central nervous system tumors enhances the efficacy of peripheral tumor cell vaccines: dependence on apoptotic pathways. J Immunol 2005;175:2730-40. [PMID: 16081851 DOI: 10.4049/jimmunol.175.4.2730] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 2.6] [Reference Citation Analysis]
36 Liabakk NB, Espevik T. Monoclonal antibodies against TRAIL. Vitam Horm 2004;67:65-79. [PMID: 15110172 DOI: 10.1016/S0083-6729(04)67005-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
37 Friedlein G, El Hage F, Vergnon I, Richon C, Saulnier P, Lécluse Y, Caignard A, Boumsell L, Bismuth G, Chouaib S, Mami-Chouaib F. Human CD5 protects circulating tumor antigen-specific CTL from tumor-mediated activation-induced cell death. J Immunol 2007;178:6821-7. [PMID: 17513730 DOI: 10.4049/jimmunol.178.11.6821] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 2.3] [Reference Citation Analysis]
38 Mami-Chouaib F, Echchakir H, Dorothée G, Vergnon I, Chouaib S. Antitumor cytotoxic T-lymphocyte response in human lung carcinoma: identification of a tumor-associated antigen. Immunol Rev 2002;188:114-21. [PMID: 12445285 DOI: 10.1034/j.1600-065x.2002.18810.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
39 Tecchio C, Huber V, Scapini P, Calzetti F, Margotto D, Todeschini G, Pilla L, Martinelli G, Pizzolo G, Rivoltini L, Cassatella MA. IFNα-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells. Blood 2004;103:3837-44. [DOI: 10.1182/blood-2003-08-2806] [Cited by in Crossref: 110] [Cited by in F6Publishing: 100] [Article Influence: 6.1] [Reference Citation Analysis]
40 Wajant H. Molecular Mode of Action of TRAIL Receptor Agonists-Common Principles and Their Translational Exploitation. Cancers (Basel) 2019;11:E954. [PMID: 31284696 DOI: 10.3390/cancers11070954] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
41 Aboulnasr F, Krogman A, Graham RP, Cummins NW, Misra A, Garcia-Rivera E, Anderson JR, Natesampillai S, Kogan N, Aravamudan M, Nie Z, Chung TDY, Buick R, Feldman AL, King RL, Novak AJ, Ansell SM, Kenderian S, Badley AD. Human Cancers Express TRAILshort, a Dominant Negative TRAIL Splice Variant, Which Impairs Immune Effector Cell Killing of Tumor Cells. Clin Cancer Res 2020;26:5759-71. [PMID: 32669373 DOI: 10.1158/1078-0432.CCR-20-0251] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
42 Savelyeva N, Allen A, Chotprakaikiat W, Harden E, Jobsri J, Godeseth R, Wang Y, Stevenson F, Ottensmeier C. Linked CD4 T Cell Help: Broadening Immune Attack Against Cancer by Vaccination. Curr Top Microbiol Immunol 2017;405:123-43. [PMID: 27704269 DOI: 10.1007/82_2016_500] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
43 Naval J, de Miguel D, Gallego-Lleyda A, Anel A, Martinez-Lostao L. Importance of TRAIL Molecular Anatomy in Receptor Oligomerization and Signaling. Implications for Cancer Therapy. Cancers (Basel) 2019;11:E444. [PMID: 30934872 DOI: 10.3390/cancers11040444] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
44 Rus V, Zernetkina V, Puliaev R, Cudrici C, Mathai S, Via CS. Increased expression and release of functional tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by T cells from lupus patients with active disease. Clin Immunol 2005;117:48-56. [PMID: 15961346 DOI: 10.1016/j.clim.2005.05.001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
45 Mace TA, Yamane N, Cheng J, Hylander BL, Repasky EA. The Potential of the Tumor Microenvironment to Influence Apo2L/TRAIL Induced Apoptosis. Immunological Investigations 2006;35:279-96. [DOI: 10.1080/08820130600745463] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
46 Morales JC, Ruiz-magaña MJ, Ruiz-ruiz C. Regulation of the resistance to TRAIL-induced apoptosis in human primary T lymphocytes: Role of NF-κB inhibition. Molecular Immunology 2007;44:2587-97. [DOI: 10.1016/j.molimm.2006.12.015] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
47 Kim HM, Kang JS, Park S, Lee K, Kim JY, Kim YJ, Hong JT, Kim Y, Han S. Antidiabetic activity of angelan isolated from Angelica gigas Nakai. Arch Pharm Res 2008;31:1489-96. [DOI: 10.1007/s12272-001-2135-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
48 Le Maux Chansac B, Missé D, Richon C, Vergnon I, Kubin M, Soria JC, Moretta A, Chouaib S, Mami-Chouaib F. Potentiation of NK cell-mediated cytotoxicity in human lung adenocarcinoma: role of NKG2D-dependent pathway. Int Immunol 2008;20:801-10. [PMID: 18441340 DOI: 10.1093/intimm/dxn038] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
49 Pordzik S, Petrovici K, Schmid C, Kroell T, Schweiger C, Köhne CH, Schmetzer H. Expression and prognostic value of FAS receptor/FAS ligand and TrailR1/TrailR2 in acute myeloid leukemia. Hematology 2011;16:341-50. [PMID: 22183068 DOI: 10.1179/102453311X13127324303353] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]